PMID-31429064 – Bremelanotide First Approval Review
Dhillon S, Keam SJ. "Bremelanotide: First Approval," Drugs, 2019;79(14):1599-1606.
Quick Reference
| Property | Value |
|---|---|
| PMID | 31429064 |
| DOI | 10.1007/s40265-019-01187-w |
| Year | 2019 |
| Journal | Drugs |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (drug approval review) |
| Peptide(s) Studied | PT-141 |
Key Findings
- Comprehensive review of bremelanotide's FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women
- Marketed as Vyleesi (AMAG Pharmaceuticals), approved June 2019
- Mechanism: melanocortin-4 receptor (MC4R) agonist acting centrally in the hypothalamus and limbic system
- Derived from Melanotan II via metabolite-based drug design — cyclic heptapeptide
- Pharmacokinetics: subcutaneous bioavailability ~100%, Tmax ~1 hour, half-life ~2.7 hours
- Approved dose: 1.75 mg SC as needed, at least 45 minutes before sexual activity
- Maximum: one dose per 24 hours, no more than 8 doses per month
- Contraindicated in uncontrolled hypertension due to transient BP elevations
- Key distinction from flibanserin: on-demand dosing vs daily administration
Study Design
Narrative review summarizing the pharmacological profile, clinical development program, regulatory pathway, and approved prescribing information for bremelanotide (Vyleesi). Covers Phase 2 and Phase 3 clinical trial data, pharmacokinetics, safety profile, and commercial positioning.
Limitations
- Review article, not primary research
- Published at time of approval; long-term post-marketing data not yet available
- Sponsored drug profile format typical of Drugs journal approval reviews
Clinical Relevance
This review provides a concise, authoritative summary of bremelanotide's pharmacology and clinical evidence at the time of FDA approval. It is a useful reference for clinicians seeking to understand the MC4R mechanism, dosing parameters, contraindications, and place in therapy relative to flibanserin. The distinction between central melanocortin-mediated arousal (PT-141) and peripheral vascular mechanisms (PDE5 inhibitors) is clinically important for patient selection.
Related
#research #narrative-review #evidence-level-V